CDC Identify, Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis

Sponsor Deadline: 

Apr 18, 2022

Letter of Intent Deadline: 

Mar 11, 2022

Sponsor: 

Centers for Disease Control and Prevention

UI Contact: 

CDC Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS) (R01)
RFA-TS-22-001
Grants.gov   https://www.grants.gov/web/grants/view-opportunity.html?oppId=336875
LOI (optional) due 3/11/2022
Application due 4/18/2022

(p. 6 of the PDF)  Eligible applicant organizations may submit more than one application to this NOFO, provided that each application is scientifically distinct.

Purpose: In this Notice of Funding Opportunity, CDC/Agency for Toxic Substances and Disease Registry ATSDR is seeking investigator-initiated research that will identify and evaluate risk factors contributing to ALS, with preferred focus on research proposals that will examine factors related to military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents. Research proposals on preferred topics can be funded under one of two funding options, Funding Option A or Funding Option B.

Funding Option A is intended to support ALS risk factor research investigations that have an existing, well substantiated evidence base and would benefit from strengthened rigorous evaluation. Examples of proposals appropriate for Funding Option A may include, but are not limited, to investigations on well substantiated environmental, genetic, and other ALS risk factors that can be strengthened by prospective and retrospective longitudinal studies with appropriately addressed confounders; studies that improve upon past investigations with increased statistical power and expanded ALS and/or control population cohorts; and studies that seek to link risk factors to clinical diagnosis, treatment, and outcomes. Awards made under Funding Option A will be funded for up to $500,000 per year (including direct and indirect costs) for a project period of up to 3 years, pending the availability of funds.

Funding Option B is intended to support novel ALS risk factor research investigations that may or may not have an existing evidence base foundation base, may be supported by limited and insuffiicient preliminary research, and are exploratory and developmental in nature. Examples of proposals appropriate for Funding Option B may include, but are not limited to, investigations on risk factors without an existing evidence base (e.g., gut microbiome and other genomic, dietary or metabolic risk factors; aviation and other radiation-related risk factors; and sports related risk factors other than TBI [e.g., strenuous physical activity]). Funding Option B may also support ALS risk factor investigations that utilize novel approaches. Awards made under Funding Option B will be funded for up to $300,000 per year (including direct and indirect costs) for a project period of up to 3 years, pending the availability of funds.

Applicants must clearly indicate in the Abstract whether the research proposal intends to fall under Funding Option A or Funding Option B.

Categories: 

Keywords: